The pilot study, conducted on 28 patients, set out to discern whether combining PET and CT images to plan intensity modulated radiation therapy, or IMRT, treatments for patients resulted in better delivery of the radiation and lower recurrence rates. The doctors fused images captured from both the PET and CT scans and found that the proposed treatment plans were very different in 14 of 16 patients whose plans had been designed using CT scanning alone. Out of the 28 patients who were followed for more than six months after treatment, 16 showed no signs of recurrence. The current standard of care for head and neck cancer patients involves surgery or radiation for early-stage cancer and some combination of radiation, surgery or chemotherapy for advanced cases. The high doses of radiation therapy that patients receive cause toxicity which can negatively impact a patients' quality of life. This study shows that IMRT, which modifies the intensity of the radiation beams to both the tumor and surrounding healthy tissue in order to avoid side effects while killing the cancer, can be used as an alternative to standard radiation therapy and could improve the patients' quality of life after cancer treatment.
"Even though it's a small sample group, this study shows the fusion of PET/CT can significantly improve treatment planning for radiation therapy and might ultimately help patients with head and neck cancer who receive radiation therapy beat their disease," said Dian Wang, M.D., Ph.D., lead author of the study and a radiation oncologist at the Medical College of Wisconsin in Milwaukee. "In addition, these patients may experience fewer side effects as the PET/CT-based target definition decreases the likelihood of including adjacent tissues that do not contain microscopic tumor cells in the high dose treatment volume. We're hoping that this study will encourage our colleagues to consider PET/CT fusion with IMRT for both initial staging and treatment planning for head and neck cancer patients."
For more information on radiation therapy for head and neck cancer, please visit www.rtanswers.org. To arrange an interview with Dr. Wang or for a copy of "Initial Experience of FDG-PET/CT Guided IMRT of Head and Neck Carcinoma," please contact Nick Lashinsky at email@example.com, 1-800-962-7876 or 703-839-7336.
ASTRO is the largest radiation oncology society in the world, with more than 8,500 members who specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, biology and physics, the Society is dedicated to the advancement of the practice of radiation oncology by promoting excellence in patient care, providing opportunities for educational and professional development, promoting research and disseminating research results and representing radiation oncology in a rapidly evolving socioeconomic healthcare environment.